EA201490031A1 - Циклоалкил-конденсированные тетрагидрохинолины в качестве модуляторов рецепторов crth - Google Patents

Циклоалкил-конденсированные тетрагидрохинолины в качестве модуляторов рецепторов crth

Info

Publication number
EA201490031A1
EA201490031A1 EA201490031A EA201490031A EA201490031A1 EA 201490031 A1 EA201490031 A1 EA 201490031A1 EA 201490031 A EA201490031 A EA 201490031A EA 201490031 A EA201490031 A EA 201490031A EA 201490031 A1 EA201490031 A1 EA 201490031A1
Authority
EA
Eurasian Patent Office
Prior art keywords
crth
cycloalkyl
modulators
receptors
present
Prior art date
Application number
EA201490031A
Other languages
English (en)
Other versions
EA025100B1 (ru
Inventor
Сяньхай Хуан
Джейсон Брубейкер
Скотт Л. Питерсон
Джон У. Батчер
Джошуа Т. Клоуз
Мишель Мартинес
Рэйчел Николя Маккосс
Дзоон О. Дзунг
Пхиенг Силипхаиванх
Хунцзюнь Чжан
Роберт Дж. Асланян
Пураккаттле Джони Биджу
Ли Дун
Ин Хуан
Кевин Д. Маккормик
Нин Шао
Вэй Чжоу
Анандан Палани
Original Assignee
Мерк Шарп И Доум Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47357455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201490031(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Мерк Шарп И Доум Корп. filed Critical Мерк Шарп И Доум Корп.
Publication of EA201490031A1 publication Critical patent/EA201490031A1/ru
Publication of EA025100B1 publication Critical patent/EA025100B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Данное изобретение предлагает определенные циклоалкил-конденсированные тетрагидрохинолины формулы (I) и их фармацевтически приемлемые соли и сложные эфиры, где R, R, R, R, R, E, Y, Z, n, u и t такие, как определены в настоящем описании. Кроме того, данное изобретение предлагает фармацевтические композиции, содержащие вышеуказанные соединения, и способы применения соединений для лечения заболеваний или состояний, ассоциированных с неконтролируемой или неадекватной стимуляцией функции CRTH.
EA201490031A 2011-06-17 2012-06-14 Циклоалкил-конденсированные тетрагидрохинолины в качестве модуляторов рецепторов crth EA025100B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161498345P 2011-06-17 2011-06-17
PCT/US2012/042336 WO2012174176A1 (en) 2011-06-17 2012-06-14 Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators

Publications (2)

Publication Number Publication Date
EA201490031A1 true EA201490031A1 (ru) 2014-12-30
EA025100B1 EA025100B1 (ru) 2016-11-30

Family

ID=47357455

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490031A EA025100B1 (ru) 2011-06-17 2012-06-14 Циклоалкил-конденсированные тетрагидрохинолины в качестве модуляторов рецепторов crth

Country Status (25)

Country Link
US (2) US20140128367A1 (ru)
EP (1) EP2720545B1 (ru)
JP (1) JP5629403B2 (ru)
KR (1) KR101599157B1 (ru)
CN (1) CN103763924B (ru)
AR (1) AR086931A1 (ru)
AU (1) AU2012271661B8 (ru)
BR (1) BR112013032557A2 (ru)
CA (1) CA2838731C (ru)
CL (1) CL2013003625A1 (ru)
CO (1) CO6821958A2 (ru)
CR (1) CR20130670A (ru)
DO (1) DOP2013000306A (ru)
EA (1) EA025100B1 (ru)
EC (1) ECSP14013156A (ru)
ES (1) ES2613644T3 (ru)
IL (1) IL229508A0 (ru)
MA (1) MA35188B1 (ru)
MX (1) MX2013014900A (ru)
NI (1) NI201300133A (ru)
PE (1) PE20140788A1 (ru)
TN (1) TN2013000471A1 (ru)
TW (1) TW201302711A (ru)
WO (1) WO2012174176A1 (ru)
ZA (1) ZA201308942B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130133219A (ko) 2010-12-23 2013-12-06 머크 샤프 앤드 돔 코포레이션 Crth₂ 수용체 조절제로서의 퀴녹살린 및 아자-퀴녹살린
EP2661265B1 (en) 2010-12-23 2017-03-08 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as crth2 receptor modulators
EP2922539B1 (en) 2012-10-01 2020-01-15 Merck Sharp & Dohme Corp. Substituted isoquinolines as crth2 receptor modulators
CN104761437B (zh) * 2015-03-31 2018-06-19 上海康鹏化学有限公司 一种4-溴-2,6-二氟三氟甲氧基苯的制备方法
CN104829556B (zh) * 2015-05-06 2018-01-23 南京信息工程大学 一种由固体光气和氨基硫脲反应制备2‑羟基‑5‑氨基‑1,3,4‑噻二唑的方法
AU2016297005A1 (en) 2015-07-23 2018-01-18 Merck Sharp & Dohme Corp. Genetic markers associated with response to CRTH2 receptor antagonists
JP7122499B2 (ja) * 2016-06-03 2022-08-22 幸久 村田 がん転移阻害剤

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU693143B2 (en) 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
EP0769958B1 (en) 1994-07-11 2003-04-16 Athena Neurosciences, Inc. Inhibitors of leukocyte adhesion
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
WO1996031206A2 (en) 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
WO1996040781A1 (en) 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
AU6311996A (en) 1995-07-06 1997-02-05 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
US5925527A (en) * 1997-02-04 1999-07-20 Trega Biosciences, Inc. Tricyclic Tetrahydroquinoline derivatives and tricyclic tetrahydroquinoline combinatorial libraries
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
WO2001027086A1 (fr) 1999-10-14 2001-04-19 Kaken Pharmaceutical Co., Ltd. Derives de tetrahydroquinoline
FR2825092B1 (fr) 2001-05-23 2005-01-14 Servier Lab Nouveau derives trycicliques de dihydro-quinoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2827206B1 (fr) 2001-07-10 2004-04-02 Nature Bois Emballages Procede et dispositif de formage de planchettes, et emballages comportant de telles planchettes
EP1505061A4 (en) * 2002-05-16 2007-08-22 Shionogi & Co CONNECTION WITH PGD-2 RECEPTOR ANTAGONISM
AU2003277285B2 (en) 2002-10-04 2007-12-13 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20040082612A1 (en) 2002-10-15 2004-04-29 Baxter Ellen W Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives
EP1556356B1 (en) * 2002-10-21 2006-05-31 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as crth2 antagonists
BRPI0411514A (pt) 2003-06-20 2006-08-01 Coley Pharm Gmbh antagonistas de receptor toll-like de molécula pequena
WO2005007094A2 (en) 2003-07-09 2005-01-27 Tularik Inc. Asthma and allergic inflammation modulators
MXPA06011540A (es) 2004-04-07 2007-01-26 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
NZ556657A (en) 2004-12-27 2010-10-29 Actelion Pharmaceuticals Ltd 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists
KR20070114762A (ko) * 2005-02-24 2007-12-04 밀레니엄 파머슈티컬스 인코퍼레이티드 염증 질환 치료를 위한 ｐｇｄ2 수용체 길항제
ES2443022T3 (es) 2005-08-12 2014-02-17 Merck Frosst Canada Inc. Derivados de indol como antagonistas del receptor CRTH2
JP2012502928A (ja) * 2008-09-22 2012-02-02 メルク カナダ インコーポレイテッド Ｃｒｔｈ２受容体アンタゴニストとしてのアザインドール誘導体
US8637541B2 (en) 2008-09-22 2014-01-28 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
CA2737483A1 (en) 2008-09-22 2010-03-25 Merck Frosst Canada Ltd. Indole derivatives as crth2 receptor antagonists
RS53268B (en) * 2009-02-24 2014-08-29 Merck Canada Inc. INDOLE DERIVATIVES AS AN ANTAGONISTS OF CRTH2 RECEPTORS
WO2012051036A1 (en) 2010-10-11 2012-04-19 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
EP2661265B1 (en) 2010-12-23 2017-03-08 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as crth2 receptor modulators
KR20130133219A (ko) 2010-12-23 2013-12-06 머크 샤프 앤드 돔 코포레이션 Crth₂ 수용체 조절제로서의 퀴녹살린 및 아자-퀴녹살린

Also Published As

Publication number Publication date
ZA201308942B (en) 2015-05-27
CN103763924B (zh) 2016-05-18
WO2012174176A1 (en) 2012-12-20
CR20130670A (es) 2014-02-04
EP2720545B1 (en) 2016-11-30
IL229508A0 (en) 2014-01-30
CN103763924A (zh) 2014-04-30
AR086931A1 (es) 2014-01-29
CL2013003625A1 (es) 2014-08-01
CO6821958A2 (es) 2013-12-31
EP2720545A1 (en) 2014-04-23
AU2012271661A8 (en) 2016-11-10
TW201302711A (zh) 2013-01-16
US8592383B2 (en) 2013-11-26
AU2012271661B8 (en) 2016-11-10
ES2613644T3 (es) 2017-05-25
EA025100B1 (ru) 2016-11-30
KR20140025576A (ko) 2014-03-04
KR101599157B1 (ko) 2016-03-02
TN2013000471A1 (en) 2015-03-30
PE20140788A1 (es) 2014-07-09
MA35188B1 (fr) 2014-06-02
CA2838731A1 (en) 2012-12-20
EP2720545A4 (en) 2015-01-14
ECSP14013156A (es) 2014-02-28
US20120329743A1 (en) 2012-12-27
JP5629403B2 (ja) 2014-11-19
MX2013014900A (es) 2014-02-17
US20140128367A1 (en) 2014-05-08
AU2012271661A1 (en) 2014-01-16
DOP2013000306A (es) 2014-06-01
CA2838731C (en) 2016-08-16
BR112013032557A2 (pt) 2020-09-24
AU2012271661B2 (en) 2016-11-03
NI201300133A (es) 2014-02-28
JP2014517041A (ja) 2014-07-17

Similar Documents

Publication Publication Date Title
EA201590879A1 (ru) Арилконденсированные и гетероарилконденсированные лактамы
EA201591087A1 (ru) Новые производные бензимидазола в качестве антагонистов рецептора ep4
EA201491012A1 (ru) Гетероциклические ингибиторы глютаминазы
EA201390576A1 (ru) Противовирусные соединения
IN2014MN02598A (ru)
EA201490031A1 (ru) Циклоалкил-конденсированные тетрагидрохинолины в качестве модуляторов рецепторов crth
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
EA201591745A1 (ru) 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантого idh
EA201391561A1 (ru) Новые соединения-модуляторы gpr-119
EA201390934A1 (ru) Композиции и способы модулирования fxr
EA201492050A1 (ru) Модуляторы ядерного транспорта и их применение
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
MX353806B (es) Quinolinas como moduladores de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr).
EA201790963A1 (ru) Противовирусные соединения
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
EA201390969A1 (ru) Модуляторы глюкагонового рецептора
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201591195A1 (ru) Новые хинолоновые производные
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
EA201391145A1 (ru) Способы получения хинолиновых соединений и фармацевтических композиций, содержащих такие соединения
EA201501122A8 (ru) Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4)
EA201500628A1 (ru) Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
EA201301019A1 (ru) Бензодиоксановые ингибиторы продуцирования лейкотриена

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU